BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25459394)

  • 1. Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study.
    Chen CA; Lin H; Weng CS; Wen KC; Lu CH; Chou HH; Huang YF; Kang CY; Ho CM; Yu MH; Chou CY
    Eur J Cancer; 2014 Dec; 50(18):3161-7. PubMed ID: 25459394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour.
    Satoh T; Aoki Y; Kasamatsu T; Ochiai K; Takano M; Watanabe Y; Kikkawa F; Takeshima N; Hatae M; Yokota H; Saito T; Yaegashi N; Kobayashi H; Baba T; Kodama S; Saito T; Sakuragi N; Sumi T; Kamura T; Yoshikawa H
    Eur J Cancer; 2015 Feb; 51(3):340-51. PubMed ID: 25559616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor.
    Kang H; Kim TJ; Kim WY; Choi CH; Lee JW; Kim BG; Bae DS
    Gynecol Oncol; 2008 Oct; 111(1):106-10. PubMed ID: 18656249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of non-testicular germ cell tumors in children and adolescents with BEP and VIP: initial results of the MAKEI 89 therapy study].
    Göbel U; Bamberg M; Engert J; Gnekow AK; Haas HJ; Jürgens H; Kühl J; Lenard HG; Lumenta C; Niethammer D
    Klin Padiatr; 1991; 203(4):236-45. PubMed ID: 1719267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
    Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
    Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89].
    Göbel U; Calaminus G; Teske C; Bamberg M; Bökkerink JP; Haas RJ; Holschneider AM; Janka-Schaub G; Jürgens H; Mittler U
    Klin Padiatr; 1993; 205(4):231-40. PubMed ID: 7690864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia].
    Song SQ; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors.
    Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    Gynecol Oncol; 2015 Jun; 137(3):418-22. PubMed ID: 25842162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients.
    Li J; Yang W; Wu X
    Gynecol Oncol; 2007 Jun; 105(3):769-75. PubMed ID: 17459461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study.
    Homesley HD; Bundy BN; Hurteau JA; Roth LM
    Gynecol Oncol; 1999 Feb; 72(2):131-7. PubMed ID: 10021290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study.
    Dimopoulos MA; Papadimitriou C; Hamilos G; Efstathiou E; Vlahos G; Rodolakis A; Aravantinos G; Kalofonos H; Kouroussis C; Gika D; Skarlos D; Bamias A
    Gynecol Oncol; 2004 Dec; 95(3):695-700. PubMed ID: 15581984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
    Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of good risk germ-cell tumours.
    Troost MM; Sternberg CN; de Wit R
    BJU Int; 2009 Nov; 104(9 Pt B):1387-91. PubMed ID: 19840018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
    Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
    J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
    Cafferty FH; White JD; Shamash J; Hennig I; Stenning SP; Huddart RA;
    Eur J Cancer; 2020 Mar; 127():139-149. PubMed ID: 32007714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors.
    Cicin I; Saip P; Guney N; Eralp Y; Ayan I; Kebudi R; Topuz E
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):210-4. PubMed ID: 19419810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
    Brown J; Shvartsman HS; Deavers MT; Ramondetta LM; Burke TW; Munsell MF; Gershenson DM
    Gynecol Oncol; 2005 May; 97(2):489-96. PubMed ID: 15863149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical Study to Determine the Dose Intensity of BEP Chemotherapy for Ovarian Malignant Germ Cell Tumors].
    Kusumoto S; Naito H; Imazu K; Kai I; Hamasaki A; Kazusa Y; Nakashima Y; Kodama M; Kumagai M; Ueda K
    Gan To Kagaku Ryoho; 2017 Mar; 44(3):255-259. PubMed ID: 28292998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.